

1 **BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 &**  
2 **Omicron variant in adults received 2-dose inactivated vaccine**

3 Nancy H. L. Leung<sup>\*1,2</sup>, Samuel M. S. Cheng<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Niki Y. M. Au<sup>1</sup>, Yvonne  
4 Y. Ng<sup>1</sup>, Leo L. H. Luk<sup>1</sup>, Karl C. K. Chan<sup>1</sup>, John K. C. Li<sup>1</sup>, Yonna W. Y. Leung<sup>1</sup>, Leo C. H.  
5 Tsang<sup>1</sup>, Sara Chaothai<sup>1</sup>, Kelvin K. H. Kwan<sup>1</sup>, Dennis K. M. Ip<sup>1</sup>, Leo L. M. Poon<sup>1,3,4</sup>, Gabriel M.  
6 Leung<sup>1,2</sup>, J. S. Malik Peiris<sup>†1,3,4</sup>, Benjamin J. Cowling<sup>\*†1,2</sup>

7 †Joint senior authors with equal contribution

8

9 **Affiliations:**

10 <sup>1</sup>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public  
11 Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special  
12 Administrative Region, China.

13 <sup>2</sup>Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong  
14 Kong Special Administrative Region, China.

15 <sup>3</sup>HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The  
16 University of Hong Kong; Hong Kong Special Administrative Region, China.

17 <sup>4</sup>Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong  
18 Special Administrative Region, China.

19

20 \*Corresponding authors: [bcowling@hku.hk](mailto:bcowling@hku.hk) and [nanleung@connect.hku.hk](mailto:nanleung@connect.hku.hk)

21

22 **Abstract**

23 Limited data exist on antibody responses to mixed vaccination strategies involving inactivated  
24 COVID-19 vaccines, particularly in the context of emerging variants. We conducted an open  
25 label trial and administered a third vaccine dose of an mRNA vaccine (BNT162b2,  
26 BioNTech/Fosun Pharma) in adults aged  $\geq 30$  years who had previously received two doses of an  
27 inactivated COVID-19 vaccine. We collected blood samples prior to administering the third dose  
28 and 28 days later, and tested for antibodies to the ancestral virus using a binding assay (ELISA),  
29 a surrogate virus neutralization test (sVNT) and a live virus plaque reduction neutralization test  
30 (PRNT), and to the Omicron variant using PRNT. A third dose of BNT162b2 substantially  
31 increased antibody titers on each assay. Mean ELISA levels increased from an optical density  
32 (OD) of 0.3 to 2.1 ( $p < 0.01$ ), and mean sVNT levels increased from an inhibition of 17% to 96%  
33 ( $p < 0.01$ ). In a random subset of 20 participants, the geometric mean PRNT<sub>50</sub> titers rose very  
34 substantially by at least 27 fold from Day 0 to Day 28 against the ancestral virus ( $p < 0.01$ ) and  
35 rose by at least 14 fold against the Omicron variant ( $p < 0.01$ ). In daily monitoring, post-  
36 vaccination reactions subsided within 7 days for over 99% of participants. In conclusion, a third  
37 dose of COVID-19 vaccination with an mRNA vaccine substantially improved antibody levels  
38 against the ancestral virus and against the Omicron variant with well-tolerated safety profile, in  
39 adults who had received two doses of inactivated vaccine 6 months earlier.

40

41

42

## 43 INTRODUCTION

44 Coronavirus disease 2019 (COVID-19) has caused major loss of life and global disruption since  
45 its emergence in late 2019. The accrual of population immunity to COVID-19 will eventually  
46 bring an end to the pandemic and allow life to return to normal. Immunity can be acquired  
47 through natural infections or, preferably, by vaccination. A number of vaccine technologies are  
48 being used for COVID-19, including inactivated virus vaccines, viral vector vaccines and mRNA  
49 vaccines (1). We and others have previously shown that antibody responses to two doses of the  
50 BNT162b2 (BioNTech/Fosun Pharma) mRNA vaccination give superior antibody responses  
51 compared to two doses of the CoronaVac (Sinovac) (aluminium hydroxide-adjuvanted)  
52 inactivated virus vaccine (2, 3). Both vaccine types confer similar T cell responses after an initial  
53 series of two doses (3).

54  
55 The emergence of variants of concern (VOCs), such as the Omicron and delta variants, and  
56 observed decrease in vaccine-induced immune responses within a few months after the second  
57 vaccine dose have resulted in the administration of third doses in some locations (4). Zeng et al.  
58 reported a placebo-controlled, randomized, double-blind phase II trial of three doses of  
59 CoronaVac at different vaccination intervals and dosages in adults aged 18-59 years, and another  
60 similar trial in older adults aged  $\geq 60$  years but with different dosages only were conducted in  
61 China (5). In the 3 $\mu$ g group (the same dosage as used in the population), neutralizing antibody  
62 titers against the ancestral virus declined to below the seropositivity cut-off 5-8 months after the  
63 second dose in both younger and older adults, but administering a third dose 8 months after  
64 second dose increased the GMT titer to 143 and 159 respectively; in addition, only grade 1 or 2  
65 solicited local and systemic adverse reactions were reported within 28 days after receiving the

66 third dose with incidence not higher than each previous dose (5). Some studies reported  
67 immunogenicity of heterologous third dose COVID-19 vaccination approximately 1-3 months  
68 shortly after recipient of two-dose inactivated vaccine, where all three doses were originally  
69 designed to be against the ancestral virus (6, 7). Pérez-Then et al. analysed plasma samples from  
70 adults collected 28 days after a BNT162b2 third dose was administered at least 4 weeks after  
71 receiving the two-dose CoronaVac, who may or may not have been previously infected with  
72 SARS-CoV-2 (6). They showed that a third dose BNT162b2 vaccination gave rise to a 1.4-fold  
73 increase in neutralizing antibodies (PRNT<sub>50</sub>) against the Omicron variant when compared to two-  
74 dose mRNA vaccine (BNT162b2 or mRNA-1273), but was less by 6.3-fold and 2.7-fold when  
75 compared to the boost against ancestral virus and the Delta variant respectively. They also  
76 reported there was no neutralizing antibodies to Omicron about 3-4 months after the two-dose  
77 Coronavac vaccination and prior to the third dose BNT162b2 vaccination. Another study by  
78 Intapiboon et al. randomized healthy adults aged 18-60 years who previously received the two-  
79 dose CoronaVac about 2.5 months earlier to either administration of a full-dose intramuscularly,  
80 half-dose intramuscularly or one-fifth-dose intradermally of a booster dose BNT162b2, and  
81 showed a median neutralizing antibody titer (PRNT<sub>50</sub>) of 563 against the delta variant 14 days  
82 after booster vaccination (7). However, no published study has examined the use of an mRNA  
83 vaccine administered as a third dose approximately 6 months after receipt of two doses of an  
84 inactivated vaccine, a vaccination program strategy being urgently considered around the world  
85 for populations who previously received inactivated vaccines especially in the context of  
86 emerging variants such as the Omicron variant. We therefore conducted a trial of the  
87 immunogenicity and reactogenicity to a third dose of an mRNA vaccine (BNT162b2) in adults  
88 who had previously received two doses of inactivated COVID-19 vaccination.

89

## 90 **RESULTS**

### 91 **Cohort description**

92 Inclusion and exclusion criteria for participant enrolment are described in the Materials and  
93 Methods section. From 13 October 2021 through 28 December 2021 we screened 436  
94 individuals, of which 373 (86%) were eligible and 315 (84%) participants enrolled. We collected  
95 baseline blood samples and administered BNT162b2 vaccination to 314 (99%) consented  
96 participants. Most of the 314 vaccinated study participants are older Chinese adults (median aged  
97 47 years, IQR 47-62), with 35% who were obese, and about one-third who reported at least one  
98 chronic medical condition including hypertension (18%), hypercholesterolemia (14%) and  
99 diabetes (7%), and almost all (98%) reported receiving two doses of CoronaVac (Sinovac) rather  
100 than other inactivated vaccines. Although adults who had received two doses of inactivated virus  
101 vaccination at least 90 days ago were eligible to enrol into our study (Fig. S1), 75% of the study  
102 participants reported receiving the second dose typically around 6-7 months earlier (Table 1).  
103 Characteristics of the 314 participants at enrolment are shown in Table 1. As of 31 December  
104 2021 we have collected Day 28 blood samples from 295 (94%) participants. A detailed flow  
105 chart of participant enrolment is provided in Fig. S1. The study is ongoing and Day 182 and 365  
106 samples will be collected in Spring 2022 and Autumn 2022 respectively.

107

### 108 **Antibodies to ancestral and Omicron virus after third-dose BNT162b2 vaccination**

109 Antibody levels measured by ELISA and sVNT against the ancestral virus for Day 0 and Day 28  
110 samples are available for 268 participants, with PRNT titers against the ancestral virus and the  
111 Omicron variant for Day 0 and Day 28 available for a random subset of 20 of these participants.

112 Figure 1 shows that a third dose of BNT substantially increased antibody titers measured by the  
113 various assays. Mean ELISA levels increased from a OD of 0.3 to 2.1 ( $p<0.01$ ), and mean sVNT  
114 levels increased from an inhibition of 17% to 96% ( $p<0.01$ ). In the subset of 20 participants for  
115 whom PRNT titers against the ancestral strain were available, the geometric mean PRNT<sub>50</sub> titer  
116 against the ancestral strain at Day 0 was 16. We could not estimate the GMT at Day 28 because  
117 18/20 (90%) samples were positive at the highest dilution of 1:320, and we noted that a GMT  
118  $\geq 320$  would correspond to a mean-fold titer rise of  $\geq 27$  from Day 0 to Day 28 ( $p<0.01$ ). The  
119 geometric mean PRNT<sub>90</sub> titer against the ancestral strain at Day 0 was 6. We could not estimate  
120 the GMT at Day 28 because 12/20 samples were positive at the highest dilution of 1:320, and we  
121 noted that a GMT  $\geq 320$  would correspond to a mean-fold titer rise of  $\geq 46$  in PRNT<sub>90</sub> titers from  
122 Day 0 to Day 28 ( $p<0.01$ ). We also measured antibody titers by PRNT against the Omicron  
123 variant. The geometric mean PRNT<sub>50</sub> titer against the Omicron strain at Day 0 was 5, and rose to  
124 73 at Day 28, a mean-fold rise of at least 14 given that the Day 0 titers were almost all assigned  
125 values of 5 corresponding to the floor of the assay at  $<10$  ( $p<0.01$ ). The geometric mean PRNT<sub>90</sub>  
126 titer against the Omicron strain at Day 0 was also 5, and rose to 25 at Day 28, a mean-fold rise of  
127 at least 5 ( $p<0.01$ ). PRNT<sub>90</sub> titers against the Omicron variant were weakly correlated with  
128 PRNT<sub>90</sub> titers against the ancestral virus (Fig. S2).

129

### 130 **Post-vaccination reactions after third-dose BNT162b2 vaccination**

131 Among the 314 participants, 299 (95%) participants reported health status for at least one day in  
132 the week following receipt of the third dose of BNT162b2, including 229 (77%) who reported  
133 every day and another 28 (9%) reported for  $\geq 7$  days. 191/299 (64%) participants reported feeling  
134 unwell for an average of 2.9 days (SD 1.8 days), and only 3 (<1%) participants reported feeling

135 unwell beyond 7 days after third dose BNT162b2 vaccination. Within the 7 days after third dose  
136 BNT162b2 vaccination, among the solicited local reactions reported by the participants, the most  
137 common were pain (46%), tenderness (44%) and swelling or hardness (23%) at the injection site  
138 (Table S1). Among the solicited systemic reactions reported, the most common were headache  
139 (24%), feverish (23%), myalgia (18%), fatigue (18%), drowsiness (17%) and malaise (10%)  
140 (Table S1). For those who reported fever  $\geq 38.0^{\circ}\text{C}$ , the median measured highest body  
141 temperature within 7 days after vaccination was  $38.3^{\circ}\text{C}$  (IQR 38.1-38.4). These symptoms  
142 usually subsided within 7 days after third dose BNT162b2 vaccination (Fig. 2). Reports of other  
143 flu-like symptoms (e.g., cough, runny nose), gastrointestinal symptoms (e.g., nausea and  
144 diarrhoea) or systematic symptoms (e.g., skin rash, joint pain and abnormal heart beat) were  
145 infrequent ( $<10\%$ ) (Table S1). Among the participants, 6 (2%) reported having sought medical  
146 consultation within one month of the third dose but none were hospitalized. Among these 6  
147 participants, 4 reported seeking medical consultation possibly for discomfort associated with  
148 vaccination within the week after vaccination, and the remaining two participants sought medical  
149 consultation due to back pain or stress outside the 7-day window.

150

## 151 **DISCUSSION**

152 Work by our own research group and others indicates that two doses of inactivated COVID-19  
153 vaccine confer moderate increases in antibody levels at one month after the second dose (2, 3).  
154 Antibody levels then gradually decline, but can be boosted by receipt of third doses. Zeng et al.  
155 showed that a third dose of inactivated vaccine given to healthy young adults at 8 months after  
156 the second dose of the same vaccine was able to boost neutralizing antibodies against the  
157 ancestral strain by about 21 fold (5). Here, we show that a third dose of mRNA vaccine

158 (BNT162b2) after two doses of inactivated virus vaccine (mostly CoronaVac), all originally  
159 formulated against the ancestral virus, was able to boost PRNT<sub>50</sub> titers against the ancestral strain  
160 by a factor of at least 27 fold, a substantial improvement over a third dose of inactivated vaccine.  
161 We also show that a third dose of BNT162b2 conferred moderate rises in PRNT<sub>50</sub> titers against  
162 the Omicron variant by a factor of at least 14 fold. While there is still a lack of consensus on the  
163 antibody threshold for protection (8-11), the PRNT<sub>50</sub> titers against Omicron at Day 28 in our  
164 study are higher than the PRNT<sub>50</sub> titers against ancestral virus after two doses of CoronaVac  
165 where the geometric mean PRNT<sub>50</sub> titer was estimated to be 27 (2). Given that two doses of  
166 inactivated vaccine were estimated to provide at least 50% protection against infection with the  
167 ancestral virus (12-14), we would expect the antibody levels against Omicron estimated in our  
168 study to correspond to somewhat more than 50% effectiveness in protection against Omicron.  
169  
170 Most of the participants in our study were older adults, and their antibody levels against Omicron  
171 were at a very low level at Day 0 prior to the third dose. Almost a third of our participants had  
172 underlying medical conditions (Table 1). The substantial boost in neutralizing antibody titers  
173 against both the ancestral virus (by at least 27 fold) and Omicron variant (by at least 14 fold)  
174 respectively by a third dose of mRNA vaccination after two-dose inactivated virus vaccination  
175 will clearly improve protection against the Omicron strain (and potentially other variant strains).  
176 Our study and the study by Pérez-Then et al. (6) showed that there was no neutralizing  
177 antibodies to Omicron about 3-4 months after the receipt of two doses of Coronavac vaccination.  
178 To the authors' knowledge, there are no published studies so far on the boost in neutralizing  
179 antibody titers against the Omicron variant by a third dose of inactivated virus vaccine about 6  
180 months after receipt of two doses of inactivated virus vaccination. A mass vaccination program



181 which targets to vaccinate populations every 6 months is a feasible alternative to annual (re-  
182 )vaccination and has been considered for influenza vaccination amid a mismatched vaccine (15),  
183 and could be a more efficient and realistic strategy than a mass vaccination program with shorter  
184 intervals. Separately, earlier studies suggested that reactogenicity for two doses of mRNA  
185 vaccines was greater than for two doses of inactivated vaccines (16). Our study shows that third  
186 dose mRNA vaccination about 6 months after second dose in older adults who previously  
187 received two doses of inactivated vaccine had higher incidence of any post-vaccination reactions  
188 compared to two doses (13) or three doses (5, 17) of inactivated vaccination, but less than two  
189 doses (18) or three doses (19) of mRNA vaccination. Earlier studies also suggest fatigue,  
190 myalgia and chill were common both after two-dose inactivated (13) or mRNA vaccines (18);  
191 nausea was common after two-dose inactivated vaccination (13); and fever and headache after  
192 two-dose mRNA vaccination (18). Similar to reactions after two-dose mRNA vaccination, in our  
193 study of third dose mRNA vaccination in older adults who previously received two doses of  
194 inactivated vaccine, feverishness and headache were commonly reported, while gastrointestinal  
195 symptoms such as nausea and diarrhoea were less commonly reported. Together, our study  
196 suggested that administering a third dose mRNA vaccine about 6-7 months after two doses of  
197 inactivated vaccines could substantially boost neutralizing antibodies against ancestral strain and  
198 the Omicron variant with well-tolerated safety profile in adults, and should be considered as an  
199 alternative to homologous third dose with an inactivated vaccine before vaccines updated with  
200 emerging variants are available.

201  
202 Our study had several limitations. We have only performed PRNT against ancestral strain and  
203 Omicron strain up to a dilution of 1:320. However, more than half of our study participants were

204 positive for antibodies to the ancestral strain at this dilution indicating antibody titers  $\geq 320$ , and  
205 we were therefore not able to determine exactly the GMT against ancestral strain after third dose  
206 mRNA vaccination but only confirm that it was  $\geq 320$ . Similarly, Day 0 samples were typically  
207 negative even at the starting dilution of 1:10, limiting our assessment of pre-vaccination GMTs.  
208 Nevertheless, we were able to conclude that third dose of mRNA vaccination would provide  
209 substantial benefits against both ancestral and Omicron strains by comparing the lower bound of  
210 the antibody boosting with the antibody level boosted after two doses of inactivated vaccination.  
211 Our results on immunogenicity may be subjected to selection bias including volunteer bias, since  
212 in Hong Kong older adults are more inclined to receive the inactivated vaccines and younger  
213 adults to mRNA vaccines (20). Indeed, while our study aimed to enrol adults aged  $\geq 30$  years,  
214 over 75% of study participants were  $\geq 47$  years old. Individuals who have received a self-funded  
215 commercial antibody test before enrolment with identified low antibody level might also have  
216 been more inclined to join studies on third dose vaccination, although only 6% of our study  
217 participants reported this as one of the major reasons for joining our study (data not shown).  
218 Separately, while we aimed to describe post-vaccination reactions comprehensively by including  
219 an exhaustive list of solicited local and systemic symptoms, our results on reactogenicity may be  
220 subjected to information bias as this was an open-label trial and it is generally perceived that  
221 there would be more post-vaccination reactions after mRNA vaccination compared to inactivated  
222 vaccination.

223

## 224 MATERIALS AND METHODS

### 225 Study design

226 This was an open-label single-arm clinical trial with allocation concealment, to measure the  
227 antibody responses and reactogenicity of an mRNA vaccine (BNT162b2) given as a third  
228 vaccine dose in adults  $\geq 30$  years of age who have previously received two doses of an  
229 inactivated COVID-19 vaccine. Note that the two-dose inactivated vaccine CoronaVac (Sinovac)  
230 and the two-dose mRNA vaccine BNT162b2 (BioNTech/Fosun Pharma) are available under the  
231 Hong Kong government's mass vaccination programme since the first quarter of 2021. Some  
232 Hong Kong citizens could have received two doses of inactivated vaccine BIBP (Sinopharm)  
233 instead if they have travelled to mainland China or overseas during the same period. The  
234 BNT162b2 (BioNTech/Fosun Pharma) vaccine used in Hong Kong, commonly known as the  
235 Pfizer-BioNTech vaccine in other parts of the world, are distributed solely by Fosun Pharma in  
236 Greater China including Hong Kong. Invitations to participate in the trial were extended to  
237 community-dwelling adults in Hong Kong through mass promotion efforts including  
238 advertisements in social media and newspapers, and invitation to and referrals from members of  
239 existing cohorts. Interested adults were invited to visit the study website where enrollment  
240 eligibility criteria were listed and to complete an online screening form for initial assessment of  
241 eligibility, and eligible individuals were invited to visit the HKUMed Community Vaccination  
242 Centre to confirm eligibility and for enrollment and vaccination. This is a single-arm study with  
243 no need for randomization, and the participants and the study staff were aware of the type of  
244 vaccination received by the participants (no blinding). The duration of participation for each  
245 participant is 12 months from the administration of the booster dose of BNT162b2. Participants

246 were provided with a free tympanic thermometer at enrolment, and a gift voucher of HK\$100  
247 (US\$13) at the blood draws on Days 28, 182 and 365.

248  
249 Individuals were eligible to participate in this trial if they had previously received two doses of  
250 an inactivated COVID-19 vaccine, for example CoronaVac (Sinovac) or BIBP (Sinopharm),  
251 with the most recent dose at least 90 days prior to enrolment. We excluded potential participants  
252 who reported a history of COVID-19 infection, who had received any dose of COVID-19  
253 vaccine other than an inactivated vaccine, or who were unsuitable to receive an mRNA vaccine  
254 including but not limited to allergies to the active substance or other ingredients of the vaccine.  
255 We also excluded potential participants with diagnosed medical conditions related to their  
256 immune system, use of medication that impairs immune system in the last 6 months except  
257 topical steroids or short-term oral steroids (course lasting  $\leq 14$  days), those who had used  
258 immunoglobulins and/or any blood products within 90 days prior to enrolment, and any females  
259 who were pregnant or intending to become pregnant in the coming 3 months.

260  
261 We collected 20 ml clotted blood specimens at the day of enrolment and vaccination (day 0) and  
262 again after 28 days, with additional blood draws planned after 182 and 365 days, to assess serum  
263 neutralizing antibody responses. After vaccination, participants were observed for 30 minutes to  
264 record any immediate events. We then asked participants to report information on immediate and  
265 delayed local or systematic events, as well as the body temperature measured using the tympanic  
266 thermometer that we provided to them after vaccination as incentive, daily within the first 7 days  
267 after receipt of BNT162N2 using an online e-diary. If the participant was still reporting any  
268 reaction on Day 7, additional daily monitoring continued for up to three additional weeks until

269 symptoms resolved. Participants were also interviewed at 28, 182 and 365 days after vaccination  
270 to collect information on medical attention required including any hospitalizations or other  
271 serious health conditions during the study. Separately, participants were interviewed at  
272 enrolment, and at 182 and 365 days after enrolment to collect information on existing medical  
273 conditions, vaccination history, reasons for choosing this type of vaccine and any confirmed  
274 COVID-19 infection during the study. Study data were collected and managed using REDCap  
275 electronic data capture tools hosted at the School of Public Health, The University of Hong Kong  
276 (21, 22).

277

## 278 **Ethics**

279 Written informed consent was obtained from all participants. The study protocol was approved  
280 by the Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong  
281 Kong West Cluster. The study was registered on Clinicaltrials.gov prior to commencement (trial  
282 number NCT05057182).

283

## 284 **Outcome measures**

285 The primary outcome measure is the vaccine (humoral) immunogenicity at 28 days after receipt  
286 of third-dose BNT162b2 vaccine, measured by the as geometric mean titer (GMT) of SARS-  
287 CoV-2 serum neutralizing antibodies using plaque reduction neutralization test (PRNT). The  
288 secondary outcome measures include: (1) the GMT of SARS-CoV-2 serum antibody titers after  
289 the third dose at Days 182 and 365 (these timepoints have not yet been reached by participants);  
290 (2) the geometric mean fold rise of SARS-CoV-2 serum neutralizing antibody titers from  
291 baseline to each post-vaccination timepoint (Day 28, 182 and 365); (3) the incidence of solicited

292 local and systemic adverse events (post-vaccination reactions) after receipt of BNT162b2  
293 vaccine given as a third vaccine dose; (4) the incidence of hospitalizations during the year after  
294 receipt of third-dose BNT162b2 vaccine.

295

### 296 **Sample size justification**

297 We aimed to enroll 300 participants into our study. While our primary outcome is the GMT at  
298 day 28 and not a comparison, we also compared the mean fold rise in GMT at day 28 versus day  
299 0 (the “strength” of the boost). Based on our preliminary data, assuming a GMT of 27 at Day 0  
300 with a standard deviation of 0.85, a sample size of 300 individuals would provide 80% power to  
301 detect a mean fold rise of 1.1 or greater at the 5% significance level.

302

### 303 **Laboratory methods**

304 Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as  
305 possible, with the optimal delivery time within 24 hours after collection for further processing.  
306 Sera were extracted from the clotted blood within 48 hours after collection, divided into 2-4  
307 aliquots, and stored at -80°C until subsequent serologic testing. We tested sera heat inactivated at  
308 56°C for 30 minutes with three assays, our in-house enzyme-linked immunosorbent assay  
309 (ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus  
310 neutralisation test (sVNT), and a plaque reduction neutralisation test (PRNT) as previously  
311 described (23-25). ELISA and sVNT were performed in all paired Day 0 and Day 28 sera  
312 available as described in the Results, and PRNT against ancestral SARS-CoV-2 virus and the  
313 Omicron variant were performed in paired Day 0 and Day 28 sera from 20 participants randomly  
314 selected from these participants using statistical program. PRNT assays were carried out using

315 ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 isolated in Hong Kong in  
316 January 2020 in Vero-E6 cells (ATCC CRL-1586) and the Pango lineage B.1.1.529 Omicron  
317 variant designated hCoV-19/Hong Kong/VM21044713\_WHP5047-S5/2021 was isolated in  
318 Vero-E6 TMRSS2 cells (Vero E6 cells overexpressing TMPRSS2, kindly provided by Dr S  
319 Matsuyama and colleagues), and the passage level 3 virus aliquots were used. Cells were  
320 maintained in Dulbecco's Modified Eagle Medium (DMEM) medium (ThermoFisher Scientific),  
321 Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (ThermoFisher  
322 Scientific, Waltham, MA, USA) and 100 U/ml of penicillin–streptomycin (ThermoFisher  
323 Scientific, Waltham, MA, USA). The virus sequences of these viruses are available in GISAID  
324 as EPI\_ISL\_412028 and EPI\_ISL\_6716902. The highest serum dilution neutralizing  $\geq 50\%$  and  
325  $\geq 90\%$  of input plaques was regarded as the 50% plaque reduction neutralization (PRNT<sub>50</sub>) and  
326 90% plaque reduction neutralization (PRNT<sub>90</sub>) titers, respectively.

327

### 328 **Statistical analysis**

329 We assessed the GMT of SARS-CoV-2 neutralizing antibodies and the mean concentrations of  
330 SARS-CoV-2 Spike RBD IgG (proxy by OD450) and surrogate virus neutralization percentages  
331 at Day 28. PRNT titers were interval censored, e.g. a sample that was able to neutralise virus at a  
332 1:20 dilution but not at a 1:40 dilution was reported as 20 but indicating the titer was  $\geq 20$  and  
333  $< 40$ . We therefore used midpoints on the log scale for measured titers. For example a measured  
334 titer of  $\geq 20$  to  $< 40$  was imputed as 28. We imputed titers  $< 10$  with the value 5 and titers  $\geq 320$   
335 with the value 452 for estimation of GMTs. We compared ratios of baseline antibody levels to  
336 different time points after receipt of BNT162b2 using Wilcoxon signed rank tests. Correlation of  
337 PRNT<sub>90</sub> titers measured at Day 28 against ancestral strain and the Omicron variant was estimated

338 by Spearman's rank correlation coefficient. Reactogenicity endpoints were described as  
339 frequency (%) for local and systemic reactions or events. The denominator used for frequency  
340 calculations was the total number of participants who reported health status for at least one day  
341 in the week following receipt of the third dose of BNT162b2. Statistical analyses were conducted  
342 using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

343

344



345 **References**

- 346 1. K. Subbarao, The success of SARS-CoV-2 vaccines and challenges ahead. *Cell Host*  
347 *Microbe* **29**, 1111-1123 (2021).
- 348 2. W. W. Lim, L. Mak, G. M. Leung, B. J. Cowling, M. Peiris, Comparative  
349 immunogenicity of mRNA and inactivated vaccines against COVID-19. *Lancet Microbe*,  
350 (2021).
- 351 3. C. K. P. Mok, C. A. Cohen, S. M. S. Cheng, C. Chen, K. O. Kwok, K. Yiu, T. O. Chan,  
352 M. Bull, K. C. Ling, Z. Dai, S. S. Ng, G. C. Y. Lui, C. Wu, G. K. Amarasinghe, D. W.  
353 Leung, S. Y. S. Wong, S. A. Valkenburg, M. Peiris, D. S. Hui, Comparison of the  
354 immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.  
355 *Respirology*, (2021).
- 356 4. Y. M. Bar-On, Y. Goldberg, M. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B.  
357 Mizrahi, S. Alroy-Preis, N. Ash, R. Milo, A. Huppert, Protection of BNT162b2 Vaccine  
358 Booster against Covid-19 in Israel. *N. Engl. J. Med.* **385**, 1393-1400 (2021).
- 359 5. G. Zeng, Q. Wu, H. Pan, M. Li, J. Yang, L. Wang, Z. Wu, D. Jiang, X. Deng, K. Chu, W.  
360 Zheng, L. Wang, W. Lu, B. Han, Y. Zhao, F. Zhu, H. Yu, W. Yin, Immunogenicity and  
361 safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in  
362 healthy adults: interim results from two single-centre, double-blind, randomised, placebo-  
363 controlled phase 2 clinical trials. *Lancet Infect. Dis.*, (2021).
- 364 6. E. Pérez-Then, C. Lucas, V. S. Monteiro, M. Miric, V. Brache, L. Cochon, C. B. F.  
365 Vogels, E. De la Cruz, A. Jorge, M. De los Santos, P. Leon, M. I. Breban, K. Billig, I.  
366 Yildirim, C. Pearson, R. Downing, E. Gagnon, A. Muyombwe, J. Razeq, M. Campbell,

- 367 A. Ko, S. B. Omer, N. D. Grubaugh, S. H. Vermund, A. Iwasaki,  
368 <https://www.medrxiv.org/content/10.1101/2021.12.27.21268459v1> (2021).
- 369 7. P. Intapiboon, P. Seepathomnarong, J. Ongarj, S. Surasombatpattana, S. Uppanisakorn, S.  
370 Mahasirimongkol, W. Sawaengdee, S. Phumiamorn, S. Sapsutthipas, P. Sangsupawanich,  
371 S. Chusri, N. Pinpathomrat, Immunogenicity and Safety of an Intradermal BNT162b2  
372 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in  
373 Healthy Population. *Vaccines* **9**, 1375 (2021).
- 374 8. K. A. Earle, D. M. Ambrosino, A. Fiore-Gartland, D. Goldblatt, P. B. Gilbert, G. R.  
375 Siber, P. Dull, S. A. Plotkin, Evidence for antibody as a protective correlate for COVID-  
376 19 vaccines. *Vaccine* **39**, 4423-4428 (2021).
- 377 9. S. Feng, D. J. Phillips, T. White, H. Sayal, P. K. Aley, S. Bibi, C. Dold, M. Fuskova, S.  
378 C. Gilbert, I. Hirsch, H. E. Humphries, B. Jepson, E. J. Kelly, E. Plested, K. Shoemaker,  
379 K. M. Thomas, J. Vekemans, T. L. Villafana, T. Lambe, A. J. Pollard, M. Voysey,  
380 Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.  
381 *Nat. Med.*, (2021).
- 382 10. P. B. Gilbert, D. C. Montefiori, A. B. McDermott, Y. Fong, D. Benkeser, W. Deng, H.  
383 Zhou, C. R. Houchens, K. Martins, L. Jayashankar, F. Castellino, B. Flach, B. C. Lin, S.  
384 O'Connell, C. McDanal, A. Eaton, M. Sarzotti-Kelsoe, Y. Lu, C. Yu, B. Borate, L. W. P.  
385 van der Laan, N. S. Hejazi, C. Huynh, J. Miller, H. M. El Sahly, L. R. Baden, M. Baron,  
386 L. De La Cruz, C. Gay, S. Kalams, C. F. Kelley, M. P. Andrasik, J. G. Kublin, L. Corey,  
387 K. M. Neuzil, L. N. Carpp, R. Pajon, D. Follmann, R. O. Donis, R. A. Koup, s. Immune  
388 Assays Team section, I. T. s. Moderna, s. Coronavirus Vaccine Prevention Network  
389 /Coronavirus Efficacy Team section, V. P. N. B. T. s. s. United States Government /Co,

- 390 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.  
391 *Science*, eab3435 (2021).
- 392 11. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K.  
393 Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are  
394 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat.*  
395 *Med.*, (2021).
- 396 12. N. Al Kaabi, Y. Zhang, S. Xia, Y. Yang, M. M. Al Qahtani, N. Abdulrazzaq, M. Al  
397 Nusair, M. Hassany, J. S. Jawad, J. Abdalla, S. E. Hussein, S. K. Al Mazrouei, M. Al  
398 Karam, X. Li, X. Yang, W. Wang, B. Lai, W. Chen, S. Huang, Q. Wang, T. Yang, Y.  
399 Liu, R. Ma, Z. M. Hussain, T. Khan, M. Saifuddin Fasihuddin, W. You, Z. Xie, Y. Zhao,  
400 Z. Jiang, G. Zhao, Y. Zhang, S. Mahmoud, I. ElTantawy, P. Xiao, A. Koshy, W. A.  
401 Zaher, H. Wang, K. Duan, A. Pan, X. Yang, Effect of 2 Inactivated SARS-CoV-2  
402 Vaccines on Symptomatic COVID-19 Infection in Adults. *JAMA* **326**, 35 (2021).
- 403 13. M. D. Tanriover, H. L. Doganay, M. Akova, H. R. Guner, A. Azap, S. Akhan, S. Kose, F.  
404 S. Erdinc, E. H. Akalin, O. F. Tabak, H. Pullukcu, O. Batum, S. Simsek Yavuz, O.  
405 Turhan, M. T. Yildirmak, I. Koksal, Y. Tasova, V. Korten, G. Yilmaz, M. K. Celen, S.  
406 Altin, I. Celik, Y. Bayindir, I. Karaoglan, A. Yilmaz, A. Ozkul, H. Gur, S. Unal, G.  
407 CoronaVac Study, Efficacy and safety of an inactivated whole-virion SARS-CoV-2  
408 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled,  
409 phase 3 trial in Turkey. *Lancet* **398**, 213-222 (2021).
- 410 14. J. H. Kim, F. Marks, J. D. Clemens, Looking beyond COVID-19 vaccine phase 3 trials.  
411 *Nat. Med.* **27**, 205-211 (2021).

- 412 15. Y. H. Tam, S. A. Valkenburg, R. Perera, J. H. F. Wong, V. J. Fang, T. W. Y. Ng, A. S. K.  
413 Kwong, W. W. S. Tsui, D. K. M. Ip, L. L. M. Poon, C. K. V. Chau, I. G. Barr, J. S. M.  
414 Peiris, B. J. Cowling, Immune responses to twice-annual influenza vaccination in older  
415 adults in Hong Kong. *Clin. Infect. Dis.* **66**, 904-912 (2018).
- 416 16. I. McDonald, S. M. Murray, C. J. Reynolds, D. M. Altmann, R. J. Boyton, Comparative  
417 systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of  
418 vaccines against SARS-CoV-2. *NPJ Vaccines* **6**, 74 (2021).
- 419 17. Y. Cao, X. Hao, X. Wang, Q. Wu, R. Song, D. Zhao, W. Song, Y. Wang, A. Yisimayi,  
420 W. Wang, W. Zhang, J. Du, H. Yu, X. S. Xie, R. Jin, Humoral immunogenicity and  
421 reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.  
422 *Cell Res.* **32**, 107-109 (2021).
- 423 18. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez,  
424 G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury,  
425 K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci,  
426 H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U.  
427 Jansen, W. C. Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA  
428 Covid-19 Vaccine. *N. Engl. J. Med.* **383**, 2603-2615 (2020).
- 429 19. A. Choi, M. Koch, K. Wu, L. Chu, L. Ma, A. Hill, N. Nunna, W. Huang, J. Oestreicher,  
430 T. Colpitts, H. Bennett, H. Legault, Y. Paila, B. Nestorova, B. Ding, D. Montefiori, R.  
431 Pajon, J. M. Miller, B. Leav, A. Carfi, R. McPhee, D. K. Edwards, Safety and  
432 immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an  
433 interim analysis. *Nat. Med.*, (2021).

- 434 20. The Government of the Hong Kong Special Administrative Region. COVID-19  
435 Vaccination Programme - Hong Kong Vaccination Dashboard,  
436 <https://www.covidvaccine.gov.hk/en/dashboard> (2021). Accessed on January 18, 2021.
- 437 21. P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, J. G. Conde, Research  
438 electronic data capture (REDCap)--a metadata-driven methodology and workflow  
439 process for providing translational research informatics support. *J. Biomed. Inform.* **42**,  
440 377-381 (2009).
- 441 22. P. A. Harris, R. Taylor, B. L. Minor, V. Elliott, M. Fernandez, L. O'Neal, L. McLeod, G.  
442 Delacqua, F. Delacqua, J. Kirby, S. N. Duda, The REDCap consortium: Building an  
443 international community of software platform partners. *J. Biomed. Inform.* **95**, 103208  
444 (2019).
- 445 23. R. A. Perera, C. K. Mok, O. T. Tsang, H. Lv, R. L. Ko, N. C. Wu, M. Yuan, W. S.  
446 Leung, J. M. Chan, T. S. Chik, C. Y. Choi, K. Leung, K. H. Chan, K. C. Chan, K. C. Li,  
447 J. T. Wu, I. A. Wilson, A. S. Monto, L. L. Poon, M. Peiris, Serological assays for severe  
448 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. *Euro Surveill.*  
449 **25**, (2020).
- 450 24. R. Perera, R. Ko, O. T. Y. Tsang, D. S. C. Hui, M. Y. M. Kwan, C. J. Brackman, E. M.  
451 W. To, H. L. Yen, K. Leung, S. M. S. Cheng, K. H. Chan, K. C. K. Chan, K. C. Li, L.  
452 Saif, V. R. Barrs, J. T. Wu, T. H. C. Sit, L. L. M. Poon, M. Peiris, Evaluation of a SARS-  
453 CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine,  
454 Cat, and Hamster Sera. *J. Clin. Microbiol.* **59**, (2021).
- 455 25. S. Cheng, C. K. P. Mok, Y. Leung, S. Ng, K. Chan, F. Ko, K. Yiu, B. Lam, E. Lau, K.  
456 Chan, L. Luk, J. Li, L. Tsang, L. Poon, C. Chen, D. Hui, M. Peiris, Neutralizing

457 antibodies against the SARS-CoV-2 Omicron variant following homologous and  
458 heterologous CoronaVac or BNT162b2 vaccination. *Nat. Med.*, (2022).

459

460

461 **Acknowledgements**

462 We gratefully acknowledge colleagues including Eileen Yu, Teresa So and Zacary Chai for  
463 technical support in preparing and conducting this study; Anson Ho for setting up the database;  
464 Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung  
465 at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination  
466 Centres at Gleneagles Hospital; and all the study participants for facilitating the study.

467

468 **Funding**

469 This project was supported by the Theme-based Research Scheme T11-712/19-N of the Research  
470 Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is  
471 supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the  
472 Research Grants Council of the Hong Kong Special Administrative Region, China. The funding  
473 bodies had no role in the design of the study, the collection, analysis, and interpretation of data,  
474 or writing of the manuscript.

475

476 **Author contributions**

477 All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are  
478 listed below according to the CRediT model:

479 Conceptualization: NHLL, GML, BJC

480 Methodology: NHLL, SMSC

481 Formal analysis: NHLL, MM-S

482 Investigation: NYMA, YYN, LLHL, KCKC, JKCL, YWYL, LCHT, SC, KKHK

483 Funding acquisition: BJC

484 Project administration: NHLL, SMSC, JSMP, BJC

485 Supervision: NHLL, SMSC, DKMI, LLMP, GML, JSMP, BJC

486 Writing – original draft: NHLL, MM-S, JSMP, BJC

487 Writing – review & editing: NHLL, SMSC, MM-S, NYMA, YYN, LLHL, KCKC, JKCL,

488 YWYL, LCHT, SC, KKHK, DKMI, LLMP, GML, JSMP, BJC.

489

#### 490 **Competing interests**

491 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and

492 Sanofi Pasteur. The authors report no other potential conflicts of interest.

493

#### 494 **Data and materials availability**


495 Anonymized raw data and R syntax to reproduce all the analyses, figures and tables in the

496 published article will be made available after publication.

497

498






499

500 **Fig. 1. Third dose of SARS-CoV-2 BNT162b2 vaccine boosts serum antibodies against**  
501 **ancestral strain and Omicron variant in adults who previously received two doses of**  
502 **inactivated vaccines. (A) ELISA for serum IgG against SARS-CoV-2 Spike receptor binding**  
503 **domain (RBD) of ancestral strain with X indicating the median level. (B) Surrogate virus**  
504 **neutralization test (sVNT) against ancestral strain with X indicating the median level. Live virus**

505 plaque reduction neutralization test (PRNT) against ancestral strain with endpoints at **(C)** 50%  
506 (PRNT<sub>50</sub>) or **(D)** 90% (PRNT<sub>90</sub>) with X indicating the median level on each assay because GMTs  
507 could not be estimated. Live virus plaque reduction neutralization test (PRNT) against Omicron  
508 variant with endpoints at **(E)** 50% (PRNT<sub>50</sub>) or **(F)** 90% (PRNT<sub>90</sub>) with X indicating the GMTs.  
509 PRNT titers are measured based on two-fold dilutions and plotted here within an interval, or <10  
510 (plotted on x-axis) or  $\geq 320$  (plotted above 320).

511



512

513 **Fig. 2. Solicited local and systemic reactions during the 7 days after third dose BNT162b2**  
 514 **vaccination in adults who previously received two doses of inactivated COVID-19 vaccine.**  
 515 **\*For solicited systemic reactions, only feverish/ fever  $\geq 38.0^{\circ}\text{C}$ / chills, and those reported in at**  
 516 **least 10% of participants are shown.**

517


518 **Table 1. Characteristics of study participants at baseline.** From 13 October 2021 through 28  
 519 December 2021, we enrolled and administered BNT162b2 vaccine as a third vaccine dose in 314  
 520 participants. ELISA and sVNT were performed in paired Day 0 and Day 28 sera available from  
 521 268 participants, and among them we randomly selected 20 participants to also perform PRNT  
 522 against ancestral SARS-CoV-2 virus and the Omicron variant. ELISA: enzyme-linked  
 523 immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction  
 524 neutralisation test.  
 525

Characteristic	Received third dose	Paired sera	Paired sera tested
	BNT162b2 vaccination (n = 314)	tested by ELISA and sVNT (n = 268)	by ELISA, sVNT & PRNT (n = 20)
	n (%)	n (%)	n (%)
<b>Female</b>	119 (38)	103 (38)	9 (45)
<b>Age (median, IQR)</b>	54 (47-62)	54 (47-62)	55 (47-64)
<b>Ethnicity</b>			
Chinese	308 (98)	264 (99)	20 (100)
<b>Obesity (for Asian populations)</b>			
Underweight (BMI < 18.5)	6 (2)	6 (2)	0 (0)
Normal (BMI 18.5 – 22.9)	112 (36)	91 (34)	4 (21)
Overweight (BMI 23.0 – 24.9)	82 (26)	72 (27)	7 (37)
Obese (BMI ≥ 25.0)	110 (35)	95 (36)	8 (42)
<b>Chronic medical conditions</b>			
Any	99 (32)	89 (33)	6 (30)
Lung disease, including COPD and asthma	1 (0)	1 (0)	0 (0)
Heart disease	7 (2)	4 (1)	0 (0)
Hypertension	58 (18)	53 (20)	5 (25)
Diabetes	23 (7)	20 (7)	1 (5)
Hypercholesterolemia	43 (14)	40 (15)	3 (15)

Kidney disease	4 (1)	4 (1)	0 (0)
Liver disease	4 (1)	3 (1)	1 (5)
Cancer	5 (2)	3 (1)	1 (5)
<b>Prior COVID-19 vaccination</b>			
2-dose CoronaVac (Sinovac)	307 (98)	261 (97)	20 (100)
2-dose BIBP (Sinopharm)	7 (2)	7 (3)	0 (0)
<b>Days between first and second dose of COVID-19 vaccination (median, IQR)</b>	28 (28-29)	28 (28-29)	28 (28-29)
<b>Days between second and third (study) dose of COVID-19 vaccination (median, IQR)</b>	205 (192-217)	204 (191-214)	197 (172-208)
<b>Smoking</b>			
Ever	34 (11)	28 (10)	5 (25)
Current	23 (7)	17 (6)	3 (15)

---

526  
527  
528  
529  
530  
531




532

533 **Fig. S1. Flow chart for this single-arm, open-label clinical trial of BNT162b2 provided as a**  
534 **third vaccine dose in adults who previously received two doses of inactivated COVID-19**  
535 **vaccine.**

536

537



538  
539 **Fig. S2. Correlation of PRNT<sub>90</sub> titers measured at Day 28 against ancestral strain and the**  
540 **Omicron variant in 20 participants randomly selected for performing PRNT.** PRNT titers  
541 are measured based on two-fold dilutions and plotted here within an interval, or <10 (plotted on  
542 axis) or  $\geq 320$  (plotted above 320). r: Spearman's rank correlation coefficient.  
543  
544

545 **Table S1. Solicited local and systemic reactions on the day after and anytime within 7 days**  
 546 **after third dose BNT162b2 vaccination in adults who previously received two doses of**  
 547 **inactivated COVID-19 vaccine.** Daily frequencies within 7 days after third dose BNT162b2  
 548 vaccination for reactions highlighted in bold are shown in Figure 2.  
 549

Post-vaccination reactions	Anytime within 7 days after third	Day 1 after third dose BNT162b2
	dose BNT162b2 vaccination (N = 299)	vaccination (N = 299)
	n (%)	n (%)
<b><u>Local reactions at the injection site</u></b>		
<b>Pain*</b>	<b>139 (46)</b>	<b>128 (43)</b>
<b>Tenderness*</b>	<b>131 (44)</b>	<b>106 (35)</b>
<b>Swelling or hardness*</b>	<b>68 (23)</b>	<b>50 (17)</b>
<b>Itchiness*</b>	<b>20 (7)</b>	<b>2 (1)</b>
<b>Redness*</b>	<b>15 (5)</b>	<b>5 (2)</b>
<b><u>Systemic reactions and general symptoms</u></b>		
<b>Feverish</b>	<b>70 (23)</b>	<b>54 (18)</b>
<b>Fever <math>\geq 38.0^{\circ}\text{C}</math></b>	<b>26 (9)</b>	<b>20 (7)</b>
<b>Chills</b>	<b>32 (11)</b>	<b>29 (10)</b>
<b>Headache</b>	<b>73 (24)</b>	<b>55 (18)</b>
<b>Myalgia</b>	<b>54 (18)</b>	<b>38 (13)</b>
<b>Fatigue</b>	<b>55 (18)</b>	<b>41 (14)</b>
<b>Drowsiness</b>	<b>50 (17)</b>	<b>37 (12)</b>
<b>Malaise</b>	<b>31 (10)</b>	<b>20 (7)</b>
Pain at the injection arm	25 (8)	14 (5)
Loss of appetite	21 (7)	12 (4)
Dizziness	21 (7)	11 (4)
Runny nose	19 (6)	12 (4)
Nasal congestion	19 (6)	9 (3)
Arthralgia	16 (5)	10 (3)
Sneezing	16 (5)	8 (3)
Sore throat	15 (5)	9 (3)
Chest discomfort	13 (4)	9 (3)
Diarrhoea	13 (4)	4 (1)
Abdominal distention	11 (4)	6 (2)
Palpitations	11 (4)	5 (2)
Insomnia	11 (4)	5 (2)
Phlegm	10 (3)	5 (2)
Nausea	9 (3)	5 (2)
Cough	8 (3)	4 (1)
Abdominal pain	7 (2)	4 (1)
Constipation	6 (2)	4 (1)
Body itching	5 (2)	2 (1)



Flushing of the face	4 (1)	3 (1)
Skin rash	3 (1)	1 (0)
Chest pain	3 (1)	0 (0)
Enlarged lymph nodes	3 (1)	0 (0)
Face swelling	2 (1)	0 (0)
Arm or leg swelling	1 (0)	1 (0)
Muscle spasms	1 (0)	1 (0)
Confusion	1 (0)	1 (0)
Dyspnea	1 (0)	0 (0)
Nosebleeds	0 (0)	0 (0)
Ageusia	0 (0)	0 (0)
Anosmia	0 (0)	0 (0)
Conjunctivitis	0 (0)	0 (0)
Vomiting	0 (0)	0 (0)
Facial drooping/ weakness	0 (0)	0 (0)
Loss of consciousness	0 (0)	0 (0)
Seizure	0 (0)	0 (0)

550

551

552

553